Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026

Core Insights - Novo Nordisk (NVO) and Eli Lilly (LLY) dominate the diabetes and obesity market, primarily through GLP-1 therapies, with Lilly's Mounjaro and Zepbound, and Novo's Ozempic, Rybelsus, and Wegovy leading the way [1][2]. Financial Performance - In 2025, Lilly's Cardiometabolic Health unit generated nearly $40 billion in revenue, contributing approximately 78% of total sales, while Novo Nordisk's Diabetes and Obesity segment generated about $44 billion, accounting for 93.6% of its total sales [2]. - Lilly's Mounjaro and Zepbound generated combined sales of $36.5 billion in 2025, representing over 50% of the company's total revenues, with strong growth trends expected to continue into 2026 [4][5]. - Novo Nordisk's sales and operating profit are projected to decline by 5-13% in 2026 due to increased competition and pricing pressures [15]. Product Pipeline and Development - Lilly has a robust pipeline with several new therapies, including orforglipron, which is expected to launch in the U.S. in Q2 2026, and is seen as a convenient alternative to injectable treatments [6][8]. - Novo Nordisk is also expanding its pipeline with candidates like CagriSema and amycretin, but recent data has raised concerns about their competitive edge against Lilly's offerings [19][20]. Market Dynamics - The competitive landscape is intensifying, with both companies facing pricing pressures and competition from smaller biotech firms developing oral GLP-1 drugs [11][13][14]. - Lilly's stock has appreciated by 17.4% over the past year, contrasting sharply with Novo Nordisk's decline of 56.4% [12][32]. Valuation and Estimates - The Zacks Consensus Estimate for Lilly's 2026 sales and EPS indicates a year-over-year increase of 25.3% and 39.9%, respectively, while Novo Nordisk's estimates suggest a decrease of 2.6% in sales and 14.9% in EPS [21][24]. - Lilly's shares trade at a higher price/earnings ratio of 30.18 compared to Novo Nordisk's 11.76, indicating a premium valuation for Lilly [25]. Analyst Sentiment - Analysts favor Lilly over Novo Nordisk, with Lilly holding a Zacks Rank of 3 (Hold) and Novo Nordisk at 4 (Sell), reflecting a more favorable outlook for Lilly [31].